Open in interactive viewer → charts, metric popovers & call review

Prenetics More Than Triples Its Loss Guide — and Leaves the Revenue Line Alone

IM8 put up $62.9M of quarterly revenue and a 4.1x return on its first cohort, so management chose to spend harder: an H2 EBITDA loss of $30–35M instead of $8–12M, with a Care Bears licensing deal and a retail pivot bolted on for 2027.
PRE · Earnings Call · 2026-11-18

The number that didn't move

Prenetics delivered the quarter it promised and then changed the promise that mattered. Q3 group revenue came in at $64.1M, up 37.9% sequentially, with IM8 at $62.9M — roughly 3.7x the year-ago quarter and just above the top of the guided range. Contribution profit reached $30.6M, a 48% contribution margin, and adjusted EBITDA loss narrowed to $12.7M, or negative 20% of revenue, from negative 39% in Q2. And then: “We have chosen to move. We now expect a second half adjusted EBITDA loss of $30 million-$35 million against the $8 million-$12 million we previously provided.” — Danny Yeung, Chief Executive Officer · 2026-11-18 That is a tripling at the midpoint, and it implies a Q4 loss of roughly $17–22M. The full-year revenue guide was reaffirmed at $220–230M, which pins Q4 at $73–83M for the group and $73–80M for IM8. That asymmetry is the whole story. An analyst asked it plainly — why raise the loss and not the revenue? The CFO's answer was unusually honest: “Rather than us raise the revenue guidance, we decided to keep the fairly wide range there and hope that that's sufficient. We also don't want to raise the mark too high to the point where we are unsure of how that will look.” — Brian Rosin, Chief Financial Officer (CFO) designate · 2026-11-18 Management is buying customers with money it can see the return on, and declining to promise the revenue those customers have not yet delivered. Whether that is discipline or a tell is the question the rest of the call is built to answer.

Cohort math as capital allocation

Prenetics has effectively replaced the income statement with a cohort ledger. On the earliest cohort — 27,000 customers acquired in Q1 2025 — every dollar of acquisition cost has returned $4.10 of gross profit in under two years. The next 91,000, acquired in Q2 and Q3 of last year, sit at roughly 2.7x and are expected to cross 3.0x in early 2027. Aggregate payback across all six cohorts is now $1.68 per dollar, up from $1.44 when General Catalyst committed in July. The current cohort pays back in about six months. Against that, acquisition marketing hit $40M in the quarter and bought 137,892 new customers at a customer cost of $285, down from $301 and the second consecutive sequential decline even as spend more than doubled from Q1. September alone added 52,696 customers. Roughly 59% of billings came from repeat orders, and the company ended the period with about 160,000 active subscriptions.

We could become profitable next quarter if we slowed our spend, but that's not in the best interest of our shareholders long term.

Brian Rosin, Chief Financial Officer (CFO) designate · 2026-11-18
The funding architecture explains the willingness. The General Catalyst financing draws 70% of monthly acquisition spend, is repaid from 70% of that cohort's gross profit, and is non-dilutive — its only cost is a payback-speed-dependent premium. In Q3 that meant $31.6M of net funding against a $27.5M operating cash burn, producing positive adjusted free cash flow of $4.1M and a cash-plus-current-financial-assets balance of $111M, up slightly. Management guided to roughly 18 months before draws and repayments converge to cash-neutral. It is a structurally clever instrument and it aligns incentives, but it also means the reported EBITDA line is now a policy variable rather than an outcome.

Retail: a reversal in one quarter

Three months ago, asked about distribution, the CEO was categorical: “if you get into retail, it's a completely different business model... there's no reason for us to get into retail right now.” — Sheng Wu Yeung · 2026-08-18 This quarter, retail is a stated pillar, targeted for shelves by the end of 2027, with a named-but-unnamed big box partner. The honest caveat: “transparently, we do not have any agreements.” — Danny Yeung, Chief Executive Officer · 2026-11-18 What changed is product. The existing two SKUs are premium, high-ticket and awkward on a shelf; the two new ones are not. Those two launches carry the 2027 story. IM8 Hydration slipped from Q4 2026 to Q1 2027, deliberately, to give it its own promotional window. And Care Bears — a 10-year exclusive worldwide licensing deal with Authentic Brands Group, starting with gummy multivitamins for children and adults, with Authentic taking equity — arrives in Q2. Neither is in the reaffirmed $400M+ 2027 IM8 guide, nor is retail, nor China, a roughly $50B supplement market the company intends to enter by end-2027. Of that $400M, about $156M is projected from existing customers and channels before a single new customer is acquired. On the existing subscriber base, management expects a 15–20% attach on Hydration — consistent with the survey work disclosed in August, when more than 20% of customers had asked for exactly these two categories.

What quietly left the story

The most interesting absence is clinical. A quarter ago, Mayo Clinic was the single highest-momentum keyword in this company's own language, with the scientific advisory board and chief medical officer front and center on the call. In August, Danny gave a timeline: “with the 2 trials that are underway for the longevity as well as gut, we expect to have results of those by Q1. And Mayo Clinic just given its academic institutions will likely take a little bit longer. But we expect those, I would say, by Q2 of Q3.” — Sheng Wu Yeung · 2026-08-18 Today those readouts are "by the first half of 2027," the Mayo study gets one passing sentence, and no scientist is on the call. The quarterly subscription language has likewise thinned into a mix statistic. This is now a performance-marketing company that occasionally does trials, not a science brand that sells supplements — and it is being priced, and defended, accordingly. There is an odd, faint confluence worth noting: the company flagged agentic commerce — testing ads inside ChatGPT, buying through AI assistants — in the same week Xcel Brands used almost identical language about the "agentic commerce realm." Small consumer brands are all staring at the same next channel. Meanwhile the operating leverage claim is real and unusual: roughly 70–75 employees against more than $200M of revenue, “roughly about $3 million revenue per employee per year” — Danny Yeung, Chief Executive Officer · 2026-11-18, with about 100 people planned at $400M. Which brings the valuation tension into focus. In August, answering a question about P&G paying nearly 6x revenue for Thorne, the CEO described Prenetics as “a $350 million, $400 million company approximately today.” — Sheng Wu Yeung · 2026-08-18 The market cap now prints near $186M — roughly half — against a business annualizing $284M of revenue out of September. The stock has de-rated hard while the operating story compounded. Management's answer to that gap is to keep spending and publish, for the first time, a long-term framework: 70–75% gross margin, 8–12% operating costs, and a 15–25% adjusted EBITDA margin at maturity, with no timeline attached. So the honest reading: the cohort machine is working and the numbers behind it are better disclosed than almost anything else in small-cap DTC. But the company has now asked investors to underwrite an accelerating loss, a licensing pivot, a retail channel it has never operated, a China entry it has not signed, and a clinical program that quietly slipped a quarter — all in the same breath as reaffirming the revenue line it was least willing to raise.